Sone, Teruki http://orcid.org/0000-0002-3257-4063
Ohnaru, Kazuhiro http://orcid.org/0000-0002-3048-7580
Sugai, Takumi
Yamashita, Akiko http://orcid.org/0000-0001-8218-0831
Okimoto, Nobukazu http://orcid.org/0000-0001-5323-0350
Inoue, Tetsuo
Matsumoto, Toshio http://orcid.org/0000-0002-0618-0941
Article History
Received: 13 December 2022
Accepted: 1 November 2023
First Online: 30 November 2023
Declarations
:
: This study was conducted in compliance with the ethical principles stated in the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by the institutional review board at each site.
: Informed consent was obtained from each participant included in the study.
: TSo has received research grants from Asahi Kasei Pharma Corp. and Teijin Pharma Ltd. and consulting fees from Kissei Pharmaceutical Co. Ltd. and Shimadzu Corp. K.O. has no conflict of interest to declare. TSu and A.Y. are employees of Teijin Pharma Ltd. N.O. has received consulting fees from Asahi Kasei Pharma Corp. and Teijin Pharma Ltd., and payments for lectures, including speakers’ bureau fees, from Asahi Kasei Pharma Corp., Amgen K.K., Chugai Pharmaceutical Co., Daiichi-Sankyo Co. Ltd., Eli Lilly Japan, and Teijin Pharma Ltd. T.I. has received consulting fees from Teijin Pharma Ltd. T.M. has received consulting fees from Amgen Inc. and Teijin Pharma Ltd.